The United Kingdom and the United States have hammered out a major trade agreement that will keep no import taxes on British pharmaceutical shipments entering the US market.
Key Provisions of the Pact
Under the terms of the agreement, the UK has committed to increase spending on medicines through the National Health Service (NHS). This pledge ensures that tariffs on these key exports will remain at nothing for a timeframe of the next three years.
This deal follows recent threats to significantly raise duties on branded pharmaceutical products, with figures discussed reaching double the cost.
"This arrangement with the Britain bolsters the worldwide climate for new treatments and brings much-needed fairness to U.S.–U.K. drug exports," a release declared.
Commercial Significance
Medicines represent one of the the United Kingdom's most significant exports to the America, which is clearly the primary market for major companies like GSK and AstraZeneca.
Statistics show that in the year leading up to September, the UK sold pharmaceutical products worth £11.1bn to the US. This amount represented 17.4% of total UK exports in that period.
"This agreement protects work, stimulates capital expenditure and sets the stage for the UK to establish itself as a global hub for biotech and pharma," a government official stated.
Detailed British Pledges
The agreement includes several key pledges from the British government:
- Higher Cost Ceiling: The UK will raise the cost ceiling at which it deems new medicines to be unaffordable by 25%.
- Boosted Medicine Funding: There is a goal to increase overall public funding on drugs from 0.3 percent of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Payback Limit: The sum drug companies must refund to the NHS to control costs will be limited at 15%. Last year, refunds exceeded twenty percent.
Industry Background
The deal takes place against a ongoing dispute between the sector and the UK government over medicine costs and approval rates.
These tensions were intensified by claims that American patients were paying a premium for the equivalent treatments than people in the UK and Europe.
Over the last 18 months, several major drug company projects in the UK have been delayed or cancelled, while major investments have been announced toward American operations.
A senior figure publicly accepted that the NHS must invest a greater share on treatments, noting that its budget allocation on drugs had declined as a percentage of its overall budget over the previous ten-year period.
